Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Methylphenidate hydrochloride or modafinil may help reduce daytime sleepiness and
improve the quality of life of patients with excessive daytime sleepiness after cancer
therapy. It is not yet known whether methylphenidate hydrochloride or modafinil are more
effective than a placebo in reducing daytime sleepiness in these patients.
PURPOSE: This randomized phase II trial is studying methylphenidate hydrochloride or
modafinil to see how well they work compared with a placebo in treating young patients with
excessive daytime sleepiness after cancer therapy.